Contact
Please use this form to send email to PR contact of this press release:
Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer
TO:
Please use this form to send email to PR contact of this press release:
Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer
TO: